Johnson & Johnson: Schizophrenia trials

The registry lists 206 Schizophrenia studies with Johnson & Johnson as lead sponsor. 2 are open to participants now and 57 have results posted.

Early Phase 1 3Phase 1 40Phase 2 12Phase 3 74Phase 4 47No phase 31(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic PatientsTerminatedNCT01137799Phase 1
• A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone PalmitateCompletedNCT01110317Phase 1
• Ketamine Challenge Study With JNJ-40411813CompletedNCT01101659Phase 1
• A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective DisorderCompletedNCT01094249Phase 1
• A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy MenCompletedNCT01060228Phase 1
• A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With SchizophreniaCompletedNCT01051531Phase 3
• InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral AntipsychoticsCompletedNCT01026285
• Schizophrenia Treatment Adherence Investigation (STAI)CompletedNCT01001481
• A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With SchizophreniaCompletedNCT00915512Phase 4
• A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS PaliperidoneCompletedNCT00892541Phase 1
• A Bioequivalence Study of 15 mg ER OROS PaliperidoneCompletedNCT00892489Phase 1
• A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese VolunteersCompletedNCT00892320Phase 1
• A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I DisorderCompletedNCT00892125Phase 1
• A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.CompletedNCT00843687Phase 3
• A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS PaliperidoneCompletedNCT00838669Phase 1
• Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.CompletedNCT00828958Phase 3
• Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With SchizophreniaCompletedNCT00821600Phase 1
• A Dose-proportionality Study of Five Tablet Strengths of ER OROS PaliperidoneCompletedNCT00796835Phase 1
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796640Phase 1
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796471Phase 1
• A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS PaliperidoneCompletedNCT00796432Phase 1
• A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release PaliperidoneCompletedNCT00796276Phase 1
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release FormulationsCompletedNCT00796185Phase 1
• A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderCompletedNCT00796081Phase 1
• A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral DoseCompletedNCT00796029Phase 1
• A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ERCompletedNCT00791713Phase 1
• A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineCompletedNCT00791622Phase 1
• A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal FunctionCompletedNCT00791401Phase 1
• A Study of QT and QTc Intervals in Patients Administered Immediate Release PaliperidoneCompletedNCT00791349Phase 1
• A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver FunctionCompletedNCT00791284Phase 1
• A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With SchizophreniaCompletedNCT00791232Phase 1
• A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IRCompletedNCT00791193Phase 1
• A Study of the Dose Proportionality of Extended Release PaliperidoneCompletedNCT00791167Phase 1
• A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleCompletedNCT00790777Phase 1
• An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable RisperidoneCompletedNCT00774085
• Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.CompletedNCT00758030Phase 1
• 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With SchizophreniaCompletedNCT00752427Phase 3
• An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With SchizophreniaCompletedNCT00728195Phase 2
• INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With SchizophreniaCompletedNCT00697658
• Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral AntipsychoticsCompletedNCT00696813
• A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.CompletedNCT00668837Phase 3
• A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic PatientsCompletedNCT00653406Phase 1/2
• A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With SchizophreniaCompletedNCT00650793Phase 3
• Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.CompletedNCT00645502Phase 1
• A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.CompletedNCT00645307Phase 3
• Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable RisperidoneCompletedNCT00644852
• A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.CompletedNCT00558298Phase 3
• An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care TreatmentCompletedNCT00526877Phase 4
• Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic PatientsTerminatedNCT00515489
• Study on the Safety of Risperidone on Obese or Overweight Patients With SchizophreniaTerminatedNCT00511628
• A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.CompletedNCT00495118Phase 3
• The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With SchizophreniaTerminatedNCT00488891
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaCompletedNCT00460512Phase 3
• RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical PracticeCompletedNCT00458367
• PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective DisordersCompletedNCT00399334
• A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.CompletedNCT00378183Phase 4
• A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic EpisodeCompletedNCT00378092Phase 4
• Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of PsychosisCompletedNCT00369239Phase 4
• Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With SchizophreniaCompletedNCT00358852
• A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of SchizophreniaCompletedNCT00350467Phase 3
• Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With SchizophreniaCompletedNCT00334126Phase 3
• A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00297388Phase 3
• A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)CompletedNCT00294008
• A Registry of Treatment Adherence for Patients With SchizophreniaCompletedNCT00283517
• ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health RegistryCompletedNCT00264069
• A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.CompletedNCT00261430Phase 4
• An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With SchizophreniaCompletedNCT00257023Phase 2
• A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With SchizophreniaCompletedNCT00253136Phase 3
• A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective DisorderCompletedNCT00253110Phase 4
• A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic SchizophreniaCompletedNCT00249223Phase 3
• A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic PatientsCompletedNCT00249171Phase 4
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic SchizophreniaCompletedNCT00249132Phase 3
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaCompletedNCT00249119Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With SchizophreniaCompletedNCT00246285Phase 3
• An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of RisperdoneCompletedNCT00246272Phase 3
• Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)CompletedNCT00246194
• A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With SchizophreniaCompletedNCT00240708Phase 3
• A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With SchizophreniaCompletedNCT00236587Phase 3
• Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by InjectionCompletedNCT00236548Phase 3
• A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00236457Phase 3
• A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00236379Phase 4
• Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective DisorderCompletedNCT00236353Phase 3
• A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)CompletedNCT00216632Phase 4
• A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset PsychosisCompletedNCT00216580Phase 3
• A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone MicrospheresCompletedNCT00216528Phase 4
• A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With SchizophreniaCompletedNCT00210769Phase 3
• A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With SchizophreniaCompletedNCT00210717Phase 3
• A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00210691Phase 3
• A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With SchizophreniaCompletedNCT00210548Phase 3
• A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With SchizophreniaCompletedNCT00119756Phase 3
• A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.CompletedNCT00111189Phase 3
• Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia PatientsCompletedNCT00105326Phase 2
• Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With SchizophreniaCompletedNCT00101634Phase 3
• Investigate Risperidone for the Treatment of Schizophrenia in AdolescentsCompletedNCT00088075Phase 3
• A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.CompletedNCT00086320Phase 3
• Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With SchizophreniaCompletedNCT00085748Phase 3
• Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With SchizophreniaCompletedNCT00083668Phase 3
• Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With SchizophreniaCompletedNCT00078039Phase 3
• A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.CompletedNCT00077727Phase 3
• Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With SchizophreniaCompletedNCT00077714Phase 3